Jasper Therapeutics, Inc. (JSPR): Total Assets
$35.78M
As of 2025-12-31
$11.80M
As of 2026-06-30
-9.6%
3-year compound annual growth
+8.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $35.78M | -55.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $79.90M | -15.8% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $94.89M | +96.2% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $48.36M | -48.4% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $93.65M | +301.0% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $23.36M | -77.0% | 2022-03-18, Balance as of period end |
| 2019-12-31 | $101.69M | n/a | 2021-05-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | $35.78M | -55.2% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $32.35M | -18.2% |
| IN8BIO, Inc. (INAB) | 2025-12-31 | $32.28M | +54.1% |
| Viskase Holdings, Inc. (VISK) | 2025-12-31 | $42.81M | -9.2% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $43.52M | -47.2% |
| CEL SCI Corp (CVM) | 2025-09-30 | $28.16M | +4.3% |
| Windtree Therapeutics Inc (WINT) | 2024-12-31 | $27.88M | -14.0% |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $46.75M | -15.3% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
Compare JSPR, INMB, INAB, VISK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗